December 16, 2012
In the Region Fewer PGW terminations Philadelphia Gas Works said Friday that 7,742 of its 479,000 residential customers are without gas service after their accounts were terminated earlier in the year for failure to pay, a reduction of 781 customers from the same time a year ago. The city-owned utility reported the numbers in its annual cold weather survey that it is required to submit to the Pennsylvania Public Utility Commission....
April 15, 2008 |
LONDON - Shares in pharmaceutical company AstraZeneca PLC soared today on news that an agreement with an Indian company will delay the release of a generic competitor to its best selling heartburn drug for six years. AstraZeneca said financial guidance for 2008 would remain unchanged, but the company's shares shot up almost 9 percent as analysts sensed less of a profit risk for the London-based drug maker. India's Ranbaxy Laboratories Ltd. had submitted an application to the U.S. Food and Drug Administration to make a generic version of esomeprazole magnesium, the active pharmaceutical ingredient in heartburn medicine Nexium.
October 20, 2000 |
It is the world's best-selling prescription drug, and for some, the bright purple pill Prilosec has become a daily essential they call Vitamin P. And like vitamins, Prilosec may soon be available without a prescription. Today, AstraZeneca P.L.C., the British drugmaker with U.S. headquarters in Wilmington, will go before a Food and Drug Administration committee to seek approval to sell an over-the-counter version of its Prilosec, a treatment for such stomach disorders as ulcers and heartburn.
April 24, 2007 |
After a series of setbacks in developing products, AstraZeneca P.L.C. said today that it would pay $15.2 billion in cash to buy MedImmune Inc. in order to gain biotechnology medicines and enter the vaccines business. AstraZeneca - Britain's second-largest drugmaker, with U.S. headquarters and about 4,500 employees near Wilmington - will pay $58 a share for MedImmune, which is a 21 percent premium to the Gaithersburg, Md., company's closing price Friday of $48.01. The deal will increase AstraZeneca's proportion of biologics drugs, derived from organisms, from 7 percent to 27 percent, add 45 products in development, and give AstraZeneca the influenza vaccine FluMist and the children's respiratory treatment Synagis.
May 3, 2007 |
Federal regulators said yesterday that they are reviewing AstraZeneca P.L.C.'s handling of alleged improper marketing and the firing of a sales director. The U.S. Department of Health and Human Services made the comment in response to the drug company's statement yesterday that it had concluded an internal investigation and would share findings with regulators. "We expect to receive further information from AstraZeneca and will follow up with them as appropriate," a department spokesman, Donald White, said, giving no more details.
July 27, 2007 |
AstraZeneca P.L.C. said yesterday that it would lay off an additional 4,600 employees, trimming its payroll 7,600, or 11 percent of its workforce, within three years. The London-based drugmaker announced in February that it would dismiss about 3,000 employees in operations and manufacturing. The company said it decided additional cuts were needed in European sales and marketing, information services and business support, and drug research and development. "We still haven't finished exploring further opportunities to reduce our cost base and improve future profitability," chief financial officer Jon Symonds told investors and analysts.
March 7, 2009 |
Shortly after new antipsychotic drugs came on the market in the late 1990s, the Food and Drug Administration started to worry that they might trigger diabetes in some patients. So in 2000, the FDA asked AstraZeneca P.L.C. and other pharmaceutical companies to share data on cases of new-onset diabetes and related illnesses in patients taking the drugs. London-based AstraZeneca, which has U.S. headquarters in Wilmington, told the FDA that patients and doctors had reported 12 new cases of diabetes and five cases of related illnesses among the 623,000 who had taken its antipsychotic drug Seroquel.
February 26, 2009 |
Does the world have the right to know about negative studies on AstraZeneca's potent antipsychotic drug Seroquel? Or whether company representatives promoted the drug for unapproved uses? And what about details of sexual relationships between Wayne Macfadden, AstraZeneca's former U.S. medical director for Seroquel, and two women who researched and wrote papers supporting the drug's safety and efficacy? A federal judge in Orlando may answer those questions as soon as today in a case stemming from personal-injury claims by 15,000 people that Seroquel triggered weight gain, diabetes, and other health problems.
April 9, 2009 |
A government panel opened the door a crack yesterday toward allowing AstraZeneca P.L.C. to sell its Seroquel XR more widely, after an emotional meeting that included stories from two families who say their loved ones died after taking the powerful antipsychotic. The Food and Drug Administration advisory committee recommended the agency approve Seroquel XR for use as an additional therapy in patients suffering from depression who do not respond adequately to their current medications.
February 9, 2001 |
AstraZeneca P.L.C. said yesterday that it still plans the U.S. launch of a replacement for its blockbuster drug Prilosec this quarter, despite continuing labeling negotiations with regulators. Nexium, a new stomach medication already on the market in nine European countries, is designed to help take the place of Prilosec, which had sales of $6.2 billion last year, up 9 percent from 1999. Nexium is the next generation of Prilosec, which could lose patent protection as early as April.